Evidence for targeting thioredoxin reductases with ferrocenyl quinone methides. A possible molecular basis for the antiproliferative effect of hydroxyferrocifens on cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8849-8859

  Citta, Anna ^a   Folda, Alessandra ^a   Bindoli, Alberto ^b   Pigeon, Pascal ^c,d,e   Top, Siden ^c,d   Vessières, Anne ^c,d   Salmain, Michèle ^c,d   Jaouen, Gérard ^c,d,e   Rigobello, Maria Pia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c SORBONNE UNIVERSITÉ   (France)

^d Université Pierre et Marie Curie   (France)

^e PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FERROCENE DERIVATIVE; FERROCENYL QUINONE METHIDE DERIVATIVE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROXYFERROCIFEN DERIVATIVE; INDENE; OXIDOREDUCTASE INHIBITOR; P [(P DIMETHYLAMINOPROPYLOXYPHENYL) 2 FERROCENYL 2 BUTENYLIDENE]BENZENONE; P [1 PHENYL 2 FERROCENYL 2 BUTENYLIDENE]BENZENONE; QUINONE DERIVATIVE; SELENOCYSTEINE; THIOREDOXIN; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; UNCLASSIFIED DRUG; CYSTAMINE; FERROCENE; FERROUS ION; GLUTATHIONE; INDOLE DERIVATIVE; ORGANOSELENIUM DERIVATIVE; QUINONE METHIDE; SELENOCYSTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; IC50; IN VITRO STUDY; JURKAT CELL LINE; MICHAEL ADDITION; MOLECULAR BIOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; NEOPLASMS; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CYSTAMINE; FERROUS COMPOUNDS; GLUTATHIONE; GLUTATHIONE REDUCTASE; HUMANS; INDOLEQUINONES; INHIBITORY CONCENTRATION 50; JURKAT CELLS; NEOPLASMS; ORGANOSELENIUM COMPOUNDS; RATS; SELENOCYSTEINE; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84923831983     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5013165     Document Type: Article

References (77)

1. Savage, P.; Stebbing, J.; Bower, M.; Crook, T. Why does cytotoxic chemotherapy cure only some cancers? Nature Clin. Pract. Oncol. 2009, 6, 43-52
2. Reedijk, J. Platinum anticancer coordination compounds: study of DNA binding inspires new drug design Eur. J. Inorg. Chem. 2009, 1303-1312
3. Dyson, P. J.; Sava, G. Metal-based antitumour drugs in the post genomic era Dalton Trans. 2006, 1929-1933
4. Sava, G.; Jaouen, G.; Hillard, E. A.; Bergamo, A. Targeted therapy vs DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs Dalton Trans. 2012, 41, 8226-8234
5. Hillard, E. A.; Jaouen, G. Bioorganometallics: future trends in drug discovery, analytical chemistry, and catalysis Organometallics 2011, 30, 20-27
6. Jaouen, G.; Vessières, A.; Top, S.; Ismail, A. A.; Butler, I. S. Metal-carbonyl fragments as a new class of markers in molecular-biology J. Am. Chem. Soc. 1985, 107, 4778-4780
7. Jaouen, G.; Beck, W.; McGlinchey, M. J. A novel field of research: bioorganometallic chemistry, origins, and founding principles. In Bioorganometallics: Biomolecules, Labeling, Medicine; Jaouen, G., Ed.; Wiley: New York, 2006; pp 1-37.
8. Hillard, E. A.; Vessières, A.; Jaouen, G. Ferrocene functionalized endocrine modulators for the treatment of cancer. In Medicinal Organometallic Chemistry, Topics in Organometallic Chemistry; Jaouen, G.; Metzler-Nolte, N., Eds.; Springer-Verlag: Berlin, 2010; vol 32, pp 81-117.
9. Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer compounds J. Med. Chem. 2011, 54, 3-25
10. Dörr, M.; Meggers, E. Metal complexes as structural templates for targeting proteins Curr. Opin. Chem. Biol. 2014, 19, 76-81
11. Barry, N. P. E.; Sadler, P. J. Exploration of the medical periodic table: towards new targets Chem. Commun. 2013, 49, 5106-5131
12. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M. P.; Bindoli, A.; Geldbach, T. J.; Marrone, A.; Re, N.; Hartinger, C. G.; Dyson, P. J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds J. Med. Chem. 2008, 51, 6773-6781
13. De Luca, A.; Hartinger, C. G.; Dyson, P. J.; Lo Bello, M.; Casini, A. A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin J. Inorg. Biochem. 2013, 119, 38-42
14. Rubbiani, R.; Schuh, E.; Meyer, A.; Lemke, J.; Wimberg, J.; Metzler-Nolte, N.; Meyer, F.; Mohr, F.; Ott, I. TrxR inhibition and antiproliferative activities of structurally diverse gold N -heterocyclic carbene complexes MedChemComm 2013, 4, 942-948
15. Oehninger, L.; Stefanopoulou, M.; Alborzinia, H.; Schur, J.; Ludewig, S.; Namikawa, K.; Muñoz-Castro, A.; Köster, R. W.; Baumann, K.; Wölfl, S.; Sheldrick, W. S.; Ott, I. Evaluation of arene ruthenium(II) N -heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules Dalton Trans. 2013, 42, 1657-1666
16. Schuh, E.; Pflüger, C.; Citta, A.; Folda, A.; Rigobello, M. P.; Bindoli, A.; Casini, A.; Mohr, F. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents J. Med. Chem. 2012, 55, 5518-5528
17. Zou, T.; Lum, C. T.; Lok, C.-N.; To, W.-P.; Low, K.-H.; Che, C.-M. A binuclear gold(I) complex with mixed bridging diphosphine and bis(N -heterocyclic carbene) ligands shows favorable thiol reactivity and inhibits tumor growth and angiogenesis in vivo Angew. Chem., Int. Ed. 2014, 53, 5810-5814
18. Top, S.; Tang, J.; Vessières, A.; Carrez, D.; Provot, C.; Jaouen, G. Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics Chem. Commun. 1996, 955-956
19. Top, S.; Dauer, B.; Vaissermann, J.; Jaouen, G. Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenyl-but-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction J. Organomet. Chem. 1997, 541, 355-361
20. Top, S.; Kaloun, E. B.; Toppi, S.; Herrbach, A.; McGlinchey, M. J.; Jaouen, G. Decomplexation of cyclopentadienylmanganese tricarbonyls under very mild conditions: a novel route to substituted cyclopentadienes and their application in organometallic synthesis Organometallics 2001, 20, 4554-4561
21. Nguyen, A.; Vessières, A.; Hillard, E. A.; Top, S.; Pigeon, P.; Jaouen, G. Ferrocifens and ferrocifenols as new potential weapons against breast cancer Chimia 2007, 61, 716-724
22. Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, M.; Jaouen, G. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines Chem.-Eur. J. 2003, 9, 5223-5236
23. Vessières, A. Metal carbonyl tracers and the ferrocifen family: two facets of bioorganometallic chemistry J. Organomet. Chem. 2013, 734, 3-16
24. Gormen, M.; Pigeon, P.; Top, S.; Vessières, A.; Plamont, M. A.; Hillard, E. A.; Jaouen, G. Facile synthesis and strong antiproliferative activity of disubstituted diphenylmethylidenyl-[3]ferrocenophanes on breast and prostate cancer cell lines MedChemComm 2010, 1, 149-151
25. Michard, Q.; Jaouen, G.; Vessières, A.; Bernard, B. A. Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines J. Inorg. Biochem. 2008, 102, 1980-1985
26. Allard, E.; Passirani, C.; Garcion, E.; Pigeon, P.; Vessières, A.; Jaouen, G.; Benoit, J. P. Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas J. Controlled Release 2008, 130, 146-153
27. Allard, E.; Huynh, N. T.; Vessières, A.; Pigeon, P.; Jaouen, G.; Benoit, J. P.; Passirani, C. Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model Int. J. Pharm. 2009, 379, 317-323
28. Laine, A. L.; Adriaenssens, E.; Vessières, A.; Jaouen, G.; Corbet, C.; Desruelles, E.; Pigeon, P.; Toillon, R. A.; Passirani, C. The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer Biomaterials 2013, 34, 6949-6956
29. Hamels, D.; Dansette, P. M.; Hillard, E. A.; Top, S.; Vessières, A.; Herson, P.; Jaouen, G.; Mansuy, D. Ferrocenyl quinone methides as strong antiproliferative agents: formation by metabolic and chemical oxidation of ferrocenyl phenols Angew. Chem., Int. Ed. 2009, 48, 9124-9126
30. Hillard, E.; Vessières, A.; Thouin, L.; Jaouen, G.; Amatore, C. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates Angew. Chem., Int. Ed. 2006, 45, 285-290
31. Messina, P.; Labbe, E.; Buriez, O.; Hillard, E. A.; Vessières, A.; Hamels, D.; Top, S.; Jaouen, G.; Frapart, Y. M.; Mansuy, D.; Amatore, C. Deciphering the activation sequence of ferrociphenol anticancer drug candidates Chem.-Eur. J. 2012, 18, 6581-6587
32. Arnér, E. S. J. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions Biochim. Biophys. Acta 2009, 1790, 495-526
33. Holmgren, A.; Lu, J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease Biochem. Biophys. Res. Commun. 2010, 396, 120-124
34. Rhee, S. G.; Kang, S. W.; Chang, T. S.; Jeong, W.; Kim, K. Peroxiredoxin, a novel family of peroxidases IUBMB Life 2001, 52, 35-41
35. Luthman, M.; Holmgren, A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization Biochemistry 1982, 21, 6628-6633
36. Rigobello, M. P.; Callegaro, M. T.; Barzon, E.; Benetti, M.; Bindoli, A. Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability Free Radical Biol. Med. 1998, 24, 370-376
37. Huber, R. E.; Criddle, R. S. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs Arch. Biochem. Biophys. 1967, 122, 164-173
38. Johansson, L.; Gafvelin, G.; Arnér, E. S. J. Selenocysteine in proteins-properties and biotechnological use Biochim. Biophys. Acta 2005, 1726, 1-13
39. Urig, S.; Becker, K. On the potential of thioredoxin reductase inhibitors for cancer therapy Semin. Cancer Biol. 2006, 16, 452-465
40. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system-from science to clinic Med. Res. Rev. 2004, 24, 40-89
41. Liu, Y.; Li, Y.; Yu, S.; Zhao, G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents Curr. Drug Targets 2012, 13, 1432-1444
42. Berners-Price, S. J.; Filipovska, A. Gold compounds as therapeutic agents for human diseases Metallomics 2011, 3, 863-873
43. Bindoli, A.; Rigobello, M. P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs Coord. Chem. Rev. 2009, 253, 1692-1707
44. Liu, W. K.; Gust, R. Metal N -heterocyclic carbene complexes as potential antitumor metallodrugs Chem. Soc. Rev. 2013, 42, 755-773
45. Cai, W. Q.; Zhang, L. W.; Song, Y. L.; Wang, B. L.; Zhang, B. X.; Cui, X. M.; Hu, G. M.; Liu, Y. P.; Wu, J. C.; Fang, J. G. Small molecule inhibitors of mammalian thioredoxin reductase Free Radical Biol. Med. 2012, 52, 257-265
46. Gan, F. F.; Kaminska, K. K.; Yang, H.; Liew, C. Y.; Leow, P. C.; So, C. L.; Tu, L. N. L.; Roy, A.; Yap, C. W.; Kang, T. S.; Chui, W. K.; Chew, E. H. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity Antioxid. Redox Signaling 2013, 19, 1149-1165
47. Rice, K. P.; Klinkerch, E. J.; Gerber, S. A.; Schleicher, T. R.; Kraus, T. J.; Buros, C. M. Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine Mol. Cell. Biochem. 2012, 370, 199-207
48. Liu, X.; Pietsch, K. E.; Sturla, S. J. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes Chem. Res. Toxicol. 2011, 24, 726-736
49. Duan, D. Z.; Zhang, B. X.; Yao, J.; Liu, Y. P.; Sun, J. Y.; Ge, C. P.; Peng, S. J.; Fang, J. G. Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase Free Radical Biol. Med. 2014, 69, 15-25
50. Duan, D.; Zhang, B.; Yao, J.; Fang, J. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells Free Radical Biol. Med. 2014, 70, 182-193
51. Bindoli, A.; Rigobello, M. P. Principles in redox signaling: from chemistry to functional significance Antioxid. Redox Signaling 2013, 18, 1557-1593
52. Arteel, G. E.; Sies, H. The biochemistry of selenium and the glutathione system Environ. Toxicol. Pharmacol. 2001, 10, 153-158
53. Brigelius-Flohé, R.; Maiorino, M. Glutathione peroxidases Biochim. Biophys. Acta 2013, 1830, 3289-3303
54. Gromer, S.; Arscott, L. D.; Williams, C. H., Jr.; Schirmer, R. H.; Becker, K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds J. Biol. Chem. 1998, 273, 20096-20101
55. Fan, P. W.; Zhang, F.; Bolton, J. L. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides Chem. Res. Toxicol. 2000, 13, 45-52
56. Fan, P. W.; Bolton, J. L. Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA Drug Metab. Dispos. 2001, 29, 891-896
57. Hamels, D. Exploration du mécanisme daction des analogues ferroceniques du tamoxifène. Ph.D. Thesis, Université Pierre et Marie Curie, Paris VI, 2010.
58. Bersani, N. A.; Merwin, J. R.; Lopez, N. I.; Pearson, G. D.; Merrill, G. F. Protein electrophoretic mobility shift assay to monitor redox state of thioredoxin in cells Methods Enzymol. 2002, 347, 317-326
59. Du, Y.; Zhang, H.; Zhang, X.; Lu, J.; Holmgren, A. Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system J. Biol. Chem. 2013, 288, 32241-32247
60. Rackham, O.; Shearwood, A. M.; Thyer, R.; McNamara, E.; Davies, S. M.; Callus, B. A.; Miranda-Vizuete, A.; Berners-Price, S. J.; Cheng, Q.; Arnér, E. S. J.; Filipovska, A. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors Free Radical Biol. Med. 2011, 50, 689-699
61. Sun, Q. A.; Wu, Y.; Zappacosta, F.; Jeang, K. T.; Lee, B. J.; Hatfield, D. L.; Gladyshev, V. N. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases J. Biol. Chem. 1999, 274, 24522-24530
62. Rigobello, M. P.; Vianello, F.; Folda, A.; Roman, C.; Scutari, G.; Bindoli, A. Differential effect of calcium ions on the cytosolic and mitochondrial thioredoxin reductase Biochem. Biophys. Res. Commun. 2006, 343, 873-878
63. Baird, L.; Dinkova-Kostova, A. T. The cytoprotective role of the Keap1-Nrf2 pathway Arch. Toxicol. 2011, 85, 241-272
64. Vessières, A.; Corbet, C.; Heldt, J. M.; Lories, N.; Jouy, N.; Laios, I.; Leclercq, G.; Jaouen, G.; Toillon, R. A. A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines J. Inorg. Biochem. 2010, 104, 503-511
65. Lu, C.; Heldt, J. M.; Guille-Collignon, M.; Lemaitre, F.; Jaouen, G.; Vessières, A.; Amatore, C. Quantitative analyses of ROS and RNS production in breast cancer cell lines incubated with ferrocifens ChemMedChem 2014, 9, 1286-1293
66. Chen, Y.; Yu, M.; Jones, D. P.; Greenamyre, J. T.; Cai, J. Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells Toxicol. Appl. Pharmacol. 2006, 216, 256-262
67. Hillard, E.; Vessières, A.; Le Bideau, F.; Plazuk, D.; Spera, D.; Huche, M.; Jaouen, G. A series of unconjugated ferrocenyl phenols: prospects as anticancer agents ChemMedChem 2006, 1, 551-559
68. Top, S.; Vessières, A.; Cabestaing, C.; Laios, I.; Leclercq, G.; Provot, C.; Jaouen, G. Studies on organometallic selective estrogen receptor modulators. (SERMs) Dual activity in the hydroxy-ferrocifen series J. Organomet. Chem. 2001, 637, 500-506
69. Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R. J.; Bolton, J. L. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation Chem. Res. Toxicol. 2005, 18, 162-173
70. Rigobello, M. P.; Bindoli, A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling Methods Enzymol. 2010, 474, 109-122
71. Flohé, L.; Gunzler, W. A. Assays of glutathione peroxidase Methods Enzymol. 1984, 105, 114-121
72. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity J. Biol. Chem. 2005, 280, 25284-25290
73. Prast-Nielsen, S.; Cebula, M.; Pader, I.; Arnér, E. S. J. Noble metal targeting of thioredoxin reductase-covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin Free Radical Biol. Med. 2010, 49, 1765-1778
74. Tietze, F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues Anal. Biochem. 1969, 27, 502-522
75. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples Methods Enzymol. 1985, 113, 548-555
76. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
77. Du, Y.; Zhang, H.; Lu, J.; Holmgren, A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose J. Biol. Chem. 2012, 287, 38210-38219